MAIA Biotechnology(US:MAIA) Globenewswire·2025-12-01 14:17Core Insights - MAIA Biotechnology, Inc. announced that its CEO and certain board members purchased approximately 182,445 shares of the company's common stock at an average price of $1.06 between November 21 and 28, 2025 [1][2] Company Overview - MAIA is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, specifically its lead program, ateganosine (THIO), which targets telomerase-positive cancer cells in non-small cell lung cancer (NSCLC) patients [4] Recent Developments - Vlad Vitoc, M.D., the Chairman and CEO, purchased 94,300 shares at an average price of $1.08, while other board members Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares at an average price of $1.04 [2] - The company reported a 38% response rate and an overall survival of 17.8 months in its Phase 2 THIO-101 clinical trial, indicating the potential of ateganosine to improve patient outcomes [3] Management Confidence - The management expressed confidence in the ongoing clinical development of ateganosine, highlighting its potential to become a new standard of care for patients with non-small cell lung cancer [3] - Board members emphasized the strategic focus and scientific momentum of the company, suggesting it is well-positioned to deliver significant value for shareholders in the future [3]